TY - JOUR
T1 - Evaluation of cationic liposomes composed of an amino acid-based lipid for neuronal transfection
AU - Obata, Yosuke
AU - Ciofani, Gianni
AU - Raffa, Vittoria
AU - Cuschieri, Alfred
AU - Menciassi, Arianna
AU - Dario, Paolo
AU - Takeoka, Shinji
N1 - Funding Information:
This work was supported by the Global Centre of Excellence (GCOE) program “Practical Chemical Wisdom” and the “High-tech Research Center” project from the Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT), and partially by the Italian Institute of Technology (IIT) Network and by the NINIVE (Non Invasive Nanotransducer for In Vivo gene therapy, STRP 033378) project, which is co-financed by the Sixth Framework Program (6FP) of the European Commission.
PY - 2010/2
Y1 - 2010/2
N2 - We investigated the ability of cationic liposomes composed of 1,5-dihexadecyl N-arginyl-L-glutamate (Arg-Glu2C16) to carry nucleic acids into neuronal cells. Such liposomes have been shown to have a remarkable capacity for transfecting immortalized cell lines. Lipoplexes between the Arg-Glu2C16 liposomes and plasmid DNA encoding green fluorescent protein (GFP) were analyzed in terms of lipoplex formation, intracellular DNA trafficking, transfection efficiency, and cytotoxicity in neuronal SH-SY5Y cells. A maximum number of cells expressing GFP was obtained with lipoplexes at a lipid-to-DNA ratio of 15. With these lipoplexes, 16% of the cells were GFP-positive, which was approximately fourfold higher than the level obtained with a commercially available transfection reagent, Lipofectamine 2000. Furthermore, as a result of the low cytotoxicity of the Arg-Glu2C16 lipoplexes, the proportion of GFP-positive cells could be increased to 25% by increasing the concentration of lipoplexes that was applied to the cells. We have demonstrated that Arg-Glu2C16, as a model cationic amino acid-based lipid, has a high capability as a gene carrier, even for neuronal transfection. From the Clinical Editor: In this study, specific cationic liposomes were characterized as nucleic acid transfection agents for neuronal cells. A fourfold higher transfection rate with low cytotoxicity was reported compared to Lipofectamine 2000, a commercial reagent. The authors conclude that the studied cationic liposomes have a high capability as a gene carrier for neuronal transfection. This may become clinically significant in future gene therapy efforts of neuronal diseases.
AB - We investigated the ability of cationic liposomes composed of 1,5-dihexadecyl N-arginyl-L-glutamate (Arg-Glu2C16) to carry nucleic acids into neuronal cells. Such liposomes have been shown to have a remarkable capacity for transfecting immortalized cell lines. Lipoplexes between the Arg-Glu2C16 liposomes and plasmid DNA encoding green fluorescent protein (GFP) were analyzed in terms of lipoplex formation, intracellular DNA trafficking, transfection efficiency, and cytotoxicity in neuronal SH-SY5Y cells. A maximum number of cells expressing GFP was obtained with lipoplexes at a lipid-to-DNA ratio of 15. With these lipoplexes, 16% of the cells were GFP-positive, which was approximately fourfold higher than the level obtained with a commercially available transfection reagent, Lipofectamine 2000. Furthermore, as a result of the low cytotoxicity of the Arg-Glu2C16 lipoplexes, the proportion of GFP-positive cells could be increased to 25% by increasing the concentration of lipoplexes that was applied to the cells. We have demonstrated that Arg-Glu2C16, as a model cationic amino acid-based lipid, has a high capability as a gene carrier, even for neuronal transfection. From the Clinical Editor: In this study, specific cationic liposomes were characterized as nucleic acid transfection agents for neuronal cells. A fourfold higher transfection rate with low cytotoxicity was reported compared to Lipofectamine 2000, a commercial reagent. The authors conclude that the studied cationic liposomes have a high capability as a gene carrier for neuronal transfection. This may become clinically significant in future gene therapy efforts of neuronal diseases.
KW - Amino lipids
KW - Cationic liposomes
KW - Gene therapy
KW - Neuronal transfection
KW - Plasmid DNA
UR - http://www.scopus.com/inward/record.url?scp=75349088429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75349088429&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2009.04.005
DO - 10.1016/j.nano.2009.04.005
M3 - Article
C2 - 19447207
AN - SCOPUS:75349088429
SN - 1549-9634
VL - 6
SP - 70
EP - 77
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 1
ER -